Ophirex, Inc
CAGE Code: 7JTR0
NCAGE Code: 7JTR0
Status: Active
Type: Commercial Supplier
Summary
Ophirex, Inc is an Active Commercial Supplier with the Cage Code 7JTR0.
Address
5643 Paradise Dr Ste 2
Corte Madera CA 94925-1815
United States
Points of Contact
No Points of Contact...
Related Information
No Related Information...
People who viewed this 'CAGE Code' also viewed...
Erickson Products Co Computer Quick Corporation Madera Group Select Press Clayton Michael And Associates Transcriptions Stat Inc Hochler Associates/Alliance For Herc Rentals Inc. Pasha Foods, Llc Vigneron, Daniel B. International Fire Protection Meadowlark Gallery Larkspur Hospitality Development And Franklin Rainwater James Malone Andy Haber The Natural Heritage Institute Jenkins And Associates Mediation Film Crew Services Inc J. Randolph Qts
Frequently Asked Questions (FAQ) for CAGE 7JTR0
- What is CAGE Code 7JTR0?
- 7JTR0 is the unique identifier used by NATO Organizations to reference the physical entity known as Ophirex, Inc located at 5643 Paradise Dr Ste 2, Corte Madera CA 94925-1815, United States.
- Who is CAGE Code 7JTR0?
- 7JTR0 refers to Ophirex, Inc located at 5643 Paradise Dr Ste 2, Corte Madera CA 94925-1815, United States.
- Where is CAGE Code 7JTR0 Located?
- CAGE Code 7JTR0 is located in Corte Madera, CA, USA.
Contracting History for CAGE 7JTR0 Most Recent 25 Records
- HT942523C0061
- Dha Ph Ii Seql Proposal H2s-0045, Title: Broad-Spectrum Snakebite Antidote: Metalloprotease Inhibition To Improve Recovery Time Following Snakebite, Medical R & D Egs 23000510
- 22 Aug 2023
- Dha Ph Ii Seql Proposal H2s-0045, Title: Broad-Spectrum Snakebite Antidote: Metalloprotease Inhibition To Improve Recovery Time Following Snakebite, Medical R & D Egs 23000510
- Army Med Res Acq Activity
- Department Of Defense (Dod)
- $1,299,779.00
- Department Of Defense (Dod)
- W81XWH20C0066
- Covid-19 Dha 2018.1 Sbir Phase Iii Medical R&D Contract Proposal Titled: "Targeting Spla2 For Treatment Of Acute Respiratory Distress Syndrome (Ards) Associated With Sars-Cov2" Log 1900053 Within Scope Increase For Expanded Clinical Trial
- 27 Apr 2021
- Covid-19 Dha 2018.1 Sbir Phase Iii Medical R&D Contract Proposal Titled: "Targeting Spla2 For Treatment Of Acute Respiratory Distress Syndrome (Ards) Associated With Sars-Cov2" Log 1900053 Within Scope Increase For Expanded Clinical Trial
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $10,571,594.00
- Department Of Defense (Dod)
- W81XWH19C0082
- Dha Sbir Ph Ii Medical R&D Contract For Proposal No. H2-0440, Titled: "Broad Spectrum Envenomation Treatment". - Modification To Add Phase Ii Enhancement.
- 10 Mar 2021
- Dha Sbir Ph Ii Medical R&D Contract For Proposal No. H2-0440, Titled: "Broad Spectrum Envenomation Treatment". - Modification To Add Phase Ii Enhancement.
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $1,525,194.76
- Department Of Defense (Dod)
- W81XWH20C0066
- Nce Modification And Dodaac Change Per Section 711 Of The 2019 Ndaa, Usamraa Transferred To Dha 10/1/2022 To Sbir Phase Iii-Covid-Ards Clinical Trial.
- 17 Jan 2023
- Nce Modification And Dodaac Change Per Section 711 Of The 2019 Ndaa, Usamraa Transferred To Dha 10/1/2022 To Sbir Phase Iii-Covid-Ards Clinical Trial.
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $10,571,594.00
- Department Of Defense (Dod)
- W81XWH20C0066
- Covid-19 Dha 2018.1 Sbir Phase Iii Medical R&D Contract Proposal Titled: "Targeting Spla2 For Treatment Of Acute Respiratory Distress Syndrome (Ards) Associated With Sars-Cov2" Log 1900053 Incorporation Of Revised Technical Proposal/Sow And Budget
- 10 Jan 2022
- Covid-19 Dha 2018.1 Sbir Phase Iii Medical R&D Contract Proposal Titled: "Targeting Spla2 For Treatment Of Acute Respiratory Distress Syndrome (Ards) Associated With Sars-Cov2" Log 1900053 Incorporation Of Revised Technical Proposal/Sow And Budget
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $10,571,594.00
- Department Of Defense (Dod)
- W81XWH22C0030
- Dcaa Dodaac Correction And Per Section 711 Of The 2019 Ndaa, Usamraa Transferred To Dha 10/1/2022.
- 2 Nov 2022
- Dcaa Dodaac Correction And Per Section 711 Of The 2019 Ndaa, Usamraa Transferred To Dha 10/1/2022.
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $13,827,499.00
- Department Of Defense (Dod)
- W81XWH20C0017
- Army Medical Research And Development Sbir Phase Iii Contract Titled Advancement Of Advancement Broad-Spectrum Snakebite Antidote. Modification P00004 Provides Additional Funds For Sow Revisions.
- 28 Jul 2021
- Army Medical Research And Development Sbir Phase Iii Contract Titled Advancement Of Advancement Broad-Spectrum Snakebite Antidote. Modification P00004 Provides Additional Funds For Sow Revisions.
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $9,070,309.00
- Department Of Defense (Dod)
- W81XWH20C0017
- Incremental Funding Modification To R And D Sbir Phase Iii To Cfd Research Corporation For Project Titled, Advancement Of Broad-Spectrum Snakebite Antidote
- 8 Feb 2022
- Incremental Funding Modification To R And D Sbir Phase Iii To Cfd Research Corporation For Project Titled, Advancement Of Broad-Spectrum Snakebite Antidote
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $9,276,449.00
- Department Of Defense (Dod)
- W81XWH22C0030
- Follow-On Phase Iii R&D Sbir
- 1 Jun 2023
- Follow-On Phase Iii R&D Sbir
- Army Med Res Acq Activity
- Department Of Defense (Dod)
- $18,913,429.96
- Department Of Defense (Dod)
- W81XWH22C0030
- Follow On Phase Iii Research And Development Sbir
- 7 Apr 2023
- Follow On Phase Iii Research And Development Sbir
- Army Med Res Acq Activity
- Department Of Defense (Dod)
- $18,913,429.96
- Department Of Defense (Dod)
- W81XWH20C0017
- Usammda Phase Iii Sbir
- 23 Aug 2023
- Usammda Phase Iii Sbir
- Army Med Res Acq Activity
- Department Of Defense (Dod)
- $9,407,618.00
- Department Of Defense (Dod)
- W81XWH20C0017
- Army Medical Research And Development Sbir Phase Iii Contract Titled Advancement Of Advancement Broad-Spectrum Snakebite Antidote. Modification P00003 Provides Incremental Funds.
- 31 Mar 2021
- Army Medical Research And Development Sbir Phase Iii Contract Titled Advancement Of Advancement Broad-Spectrum Snakebite Antidote. Modification P00003 Provides Incremental Funds.
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $9,070,309.00
- Department Of Defense (Dod)
- W81XWH22C0030
- Follow On Phase Iii Research And Development Sbir For Project Titled, Broad-Spectrum Snakebite Antidote: Oral Product Development And Iv Clinical Study
- 5 Apr 2022
- Follow On Phase Iii Research And Development Sbir For Project Titled, Broad-Spectrum Snakebite Antidote: Oral Product Development And Iv Clinical Study
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $13,827,499.00
- Department Of Defense (Dod)
- W81XWH20C0017
- Medical Research And Development Sbir Phase Iii Contract To Ophirex.
- 30 Jan 2023
- Medical Research And Development Sbir Phase Iii Contract To Ophirex.
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $9,407,618.00
- Department Of Defense (Dod)